The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3

NCT00000825 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

72

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Aldesleukin

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)